Artemis Investment Management LLP Purchases Shares of 125,652 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Artemis Investment Management LLP purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 125,652 shares of the biopharmaceutical company’s stock, valued at approximately $8,018,000. Artemis Investment Management LLP owned approximately 0.10% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in HALO. CBIZ Investment Advisory Services LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Bessemer Group Inc. increased its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Finally, Park Place Capital Corp increased its holdings in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.6%

Shares of HALO stock opened at $52.21 on Friday. The business’s 50 day moving average is $56.02 and its two-hundred day moving average is $56.38. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The company has a market capitalization of $6.43 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 0.35 and a beta of 1.19. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the business posted $0.79 EPS. The company’s revenue was up 35.2% on a year-over-year basis. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Leerink Partnrs downgraded Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, May 7th. Leerink Partners downgraded Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. Finally, Benchmark downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and an average target price of $61.90.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $52.96, for a total value of $1,059,200.00. Following the completion of the sale, the chief executive officer now directly owns 733,719 shares of the company’s stock, valued at $38,857,758.24. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director now directly owns 28,611 shares of the company’s stock, valued at $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock valued at $2,437,501 in the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.